Actively Recruiting
PET/CT for Trop2 ADC Response Evaluation Cancers
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-07-15
50
Participants Needed
1
Research Sites
112 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
CONDITIONS
Official Title
PET/CT for Trop2 ADC Response Evaluation Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Histologically or cytologically confirmed metastatic breast cancer previously treated with systemic therapy, supported by imaging, tumor markers, or pathology reports
- Presence of at least one measurable lesion according to RECIST version 1.1
- Willingness to undergo serial 68Ga-MY6349 PET/CT scans before and during Trop2-ADC therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Ability to provide written informed consent and assent as required by the Clinical Research Ethics Committee
You will not qualify if you...
- Evidence of significantly impaired liver or kidney function
- Estimated life expectancy of less than 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
L
Liang Zhao, phd
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here